Atrium Health Union
- Type
- Teaching hospital
- Where
- MONROE, NC
- Medicare CCN
- 340130
- Received
- $3,860,789 in 243 records, 2025 ($719,200 general, $3,141,588 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 52 | $719,200 |
| 2025 | Research payment | 191 | $3,141,588 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 12 | $1,729,426 | 2025 |
| Janssen Research & Development, LLC | 137 | $1,023,368 | 2025 |
| Medical Device Business Services, Inc. | 4 | $321,177 | 2025 |
| Gilead Sciences, Inc. | 4 | $302,961 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $290,164 | 2025 |
| JAZZ PHARMACEUTICALS INC. | 13 | $57,683 | 2025 |
| UCB SA | 2 | $32,703 | 2025 |
| Ethicon US, LLC | 4 | $21,500 | 2025 |
| Ethicon Inc. | 1 | $15,000 | 2025 |
| ABBVIE INC. | 9 | $13,259 | 2025 |
| Masimo Corporation | 25 | $11,723 | 2025 |
| CSL Behring | 5 | $10,562 | 2025 |
| Janssen Biotech, Inc. | 3 | $9,500 | 2025 |
| Insmed, Inc. | 5 | $6,170 | 2025 |
| Peerless Surgical Inc. | 1 | $4,331 | 2025 |
| BIOTRONIK INC. | 2 | $3,026 | 2025 |
| ERBE USA Inc | 1 | $3,000 | 2025 |
| DePuy Synthes Sales Inc. | 1 | $3,000 | 2025 |
| Stryker Corporation | 1 | $1,184 | 2025 |
| Otsuka America Pharmaceutical, Inc. | 1 | $750 | 2025 |
| Barco, Inc. | 1 | $296 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 191 | $3,141,588 |
| Grant | 5 | $615,138 |
| Space rental or facility fees (teaching hospital only) | 17 | $78,016 |
| Long term medical supply or device loan | 25 | $11,723 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $11,000 |
| Education | 1 | $3,000 |
| Food and Beverage | 1 | $296 |
| Debt forgiveness | 1 | $26 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $651,108 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable o | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $623,860 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $18,435 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $17,540 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $9,975 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $8,610 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2025 |
| 2025-12-31 | ABBVIE INC. | $4,200 | Research payment | In-kind items and services | First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple | 2025 | |
| 2025-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-12-31 | ABBVIE INC. | $550 | Research payment | In-kind items and services | A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies | 2025 | |
| 2025-12-18 | Janssen Research & Development, LLC | $12,202 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-12-18 | Janssen Research & Development, LLC | $5,697 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-12-18 | Janssen Research & Development, LLC | $1,109 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-12-17 | Janssen Research & Development, LLC | $403 | Research payment | Cash or cash equivalent | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasi | 2025 | |
| 2025-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | $7,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-12-12 | Janssen Biotech, Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2025 | |
| 2025-12-10 | Merck Sharp & Dohme LLC | $131,607 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2025 |
| 2025-12-09 | Gilead Sciences, Inc. | $134,927 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-01 | Merck Sharp & Dohme LLC | $2,732 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2025 |
| 2025-11-30 | BIOTRONIK INC. | $26 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-11-28 | JAZZ PHARMACEUTICALS INC. | $4,276 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannab | 2025 |
| 2025-11-27 | Janssen Research & Development, LLC | $4,548 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-11-27 | Janssen Research & Development, LLC | $1,287 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-11-27 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-11-27 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-11-24 | Janssen Research & Development, LLC | $9,463 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2025 |
| 2025-11-24 | Janssen Research & Development, LLC | $403 | Research payment | Cash or cash equivalent | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasi | 2025 | |
| 2025-11-20 | Ethicon Inc. | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Harmonic Device, Energy | 2025 | |
| 2025-11-20 | Ethicon US, LLC | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Echelon; Endopath Device, Endo-Mechanical | 2025 | |
| 2025-11-14 | Takeda Pharmaceuticals U.S.A., Inc. | $625 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HO | 2025 | |
| 2025-11-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,698 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY INVESTIGATING THE SAFETY OF TAK-079 IN COMBINATION WITH BACKBONE REGIMENS FOR | 2025 | |
| 2025-11-12 | JAZZ PHARMACEUTICALS INC. | $3,421 | Research payment | Cash or cash equivalent | Modeyso Drug, HEMATOLOGY/ONCOLOGY | ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Random | 2025 |
| 2025-11-07 | Janssen Research & Development, LLC | $6,400 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-11-07 | ERBE USA Inc | $3,000 | Education | Cash or cash equivalent | vio3 Device, Gastroenterology | 2025 | |
| 2025-11-06 | Medical Device Business Services, Inc. | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-05 | Merck Sharp & Dohme LLC | $14,875 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | The POUR Study: Effects of Neuromuscular Reversal Agents on Postoperative Urinary Retention (POUR) Following Laparoscopi | 2025 |
| 2025-11-05 | JAZZ PHARMACEUTICALS INC. | $2,991 | Research payment | Cash or cash equivalent | Modeyso Drug, HEMATOLOGY/ONCOLOGY | ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Random | 2025 |
| 2025-11-03 | Ethicon US, LLC | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VISTASEAL Biological, Biosurgical | 2025 | |
| 2025-10-31 | Janssen Research & Development, LLC | $2,727 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-10-29 | Medical Device Business Services, Inc. | $312,177 | Grant | In-kind items and services | Neuwave Device, Ablation System | 2025 | |
| 2025-10-29 | Medical Device Business Services, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MATRIXMIDFACE Device, CMF-Trauma | 2025 | |
| 2025-10-27 | Janssen Research & Development, LLC | $9,160 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-10-27 | Ethicon US, LLC | $6,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VISTASEAL Biological, Biosurgical | 2025 | |
| 2025-10-17 | Takeda Pharmaceuticals U.S.A., Inc. | $39,248 | Research payment | Cash or cash equivalent | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2025 | |
| 2025-10-06 | Janssen Research & Development, LLC | $6,372 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-10-03 | Janssen Research & Development, LLC | $8,885 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-09-26 | Janssen Research & Development, LLC | $5,999 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-09-26 | Medical Device Business Services, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-26 | JAZZ PHARMACEUTICALS INC. | $629 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannab | 2025 |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-26 | Masimo Corporation | $445 | Long term medical supply or device loan | In-kind items and services | SET and rainbow SET Device, Devices | 2025 | |
| 2025-09-22 | Janssen Research & Development, LLC | $3,427 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2025 | |
| 2025-09-22 | Janssen Biotech, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-16 | Otsuka America Pharmaceutical, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-15 | Takeda Pharmaceuticals U.S.A., Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-10 | JAZZ PHARMACEUTICALS INC. | $2,771 | Research payment | Cash or cash equivalent | Modeyso Drug, HEMATOLOGY/ONCOLOGY | ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Random | 2025 |
| 2025-09-10 | JAZZ PHARMACEUTICALS INC. | $1,450 | Research payment | Cash or cash equivalent | Modeyso Drug, HEMATOLOGY/ONCOLOGY | ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Random | 2025 |
| 2025-09-08 | Janssen Research & Development, LLC | $23,126 | Research payment | Cash or cash equivalent | Levine Alliance Partnership | 2025 | |
| 2025-09-08 | Janssen Research & Development, LLC | $1,300 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2025 | |
| 2025-09-04 | Janssen Research & Development, LLC | $33,373 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-09-04 | Janssen Research & Development, LLC | $3,856 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-09-04 | Ethicon US, LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HAMMERLOCK Device, Trauma | 2025 | |
| 2025-09-04 | ABBVIE INC. | $256 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2025 |
| 2025-09-04 | ABBVIE INC. | $65 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2025 |
| 2025-09-02 | Gilead Sciences, Inc. | $85,879 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-09-02 | DePuy Synthes Sales Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HAMMERLOCK Device, Trauma | 2025 | |
| 2025-09-01 | Janssen Research & Development, LLC | $11,945 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-08-28 | Janssen Research & Development, LLC | $3,895 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2025 | |
| 2025-08-26 | Gilead Sciences, Inc. | $66,972 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-08-21 | Janssen Research & Development, LLC | $2,500 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Openlabel Intravenous Induction Treatment | 2025 |
| 2025-08-15 | Janssen Research & Development, LLC | $49,077 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bort | 2025 |
| 2025-08-11 | Janssen Research & Development, LLC | $1,191 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2025 | |
| 2025-07-31 | Janssen Research & Development, LLC | $11,159 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-07-31 | Janssen Research & Development, LLC | $10,797 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $1,858 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-30 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | $15,256 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | $442 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | $201 | Research payment | Cash or cash equivalent | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasi | 2025 | |
| 2025-07-24 | JAZZ PHARMACEUTICALS INC. | $3,583 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannab | 2025 |
| 2025-07-24 | Janssen Research & Development, LLC | $242 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2025 | |
| 2025-07-21 | Merck Sharp & Dohme LLC | $150,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable o | 2025 |
| 2025-07-14 | CSL Behring | $6,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-07-14 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-07-11 | Janssen Research & Development, LLC | $3,185 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2025 |
| 2025-07-11 | Janssen Research & Development, LLC | $280 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Openlabel Intravenous Induction Treatment | 2025 |
| 2025-07-07 | Janssen Research & Development, LLC | $1,092 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2025 | |
| 2025-07-04 | Janssen Research & Development, LLC | $11,188 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-07-04 | Janssen Research & Development, LLC | $5,202 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2025 | |
| 2025-07-03 | ABBVIE INC. | $256 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2025 |
| 2025-06-30 | Janssen Research & Development, LLC | $12,304 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-06-30 | Janssen Research & Development, LLC | $442 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2025 |
| 2025-06-26 | Janssen Research & Development, LLC | $3,548 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2025 | |
| 2025-06-26 | Janssen Research & Development, LLC | $532 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2025 | |
| 2025-06-25 | Janssen Research & Development, LLC | $201 | Research payment | Cash or cash equivalent | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasi | 2025 | |
| 2025-06-23 | Takeda Pharmaceuticals U.S.A., Inc. | $16,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-06-13 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-06-13 | CSL Behring | $1,562 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-06-13 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2025 |
| 2025-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | $31,429 | Research payment | Cash or cash equivalent | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2025 | |
| 2025-06-06 | Janssen Research & Development, LLC | $4,823 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-05-30 | Janssen Research & Development, LLC | $13,010 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-05-29 | Janssen Research & Development, LLC | $8,168 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-05-29 | Stryker Corporation | $1,184 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LATITUDE EV Device, TRAUMA & EXTREMITIES | 2025 | |
| 2025-05-23 | Janssen Research & Development, LLC | $46,252 | Research payment | Cash or cash equivalent | Levine Alliance Partnership | 2025 | |
| 2025-05-23 | Janssen Research & Development, LLC | $1,300 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2025 | |
| 2025-05-22 | Janssen Research & Development, LLC | $3,427 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2025 | |
| 2025-05-22 | JAZZ PHARMACEUTICALS INC. | $2,919 | Research payment | Cash or cash equivalent | EPIDIOLEX Drug, NEUROLOGY | A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannab | 2025 |
| 2025-05-21 | JAZZ PHARMACEUTICALS INC. | $1,782 | Research payment | Cash or cash equivalent | Modeyso Drug, HEMATOLOGY/ONCOLOGY | ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Random | 2025 |
| 2025-05-14 | Merck Sharp & Dohme LLC | $99,930 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients with Metastatic HER2-Negative Breast Cancer (The PePPy Trial) | 2025 |
| 2025-05-08 | Janssen Research & Development, LLC | $18,986 | Research payment | Cash or cash equivalent | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-I | 2025 | |
| 2025-05-05 | Janssen Research & Development, LLC | $4,426 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2025 | |
| 2025-05-05 | Janssen Research & Development, LLC | $810 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide a | 2025 |
| 2025-05-02 | Janssen Research & Development, LLC | $25,221 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-05-02 | Janssen Biotech, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ERLEADA Drug, Oncology | 2025 | |
| 2025-05-01 | Janssen Research & Development, LLC | $4,160 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-05-01 | Janssen Research & Development, LLC | $3,081 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $3,901 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2025 | |
| 2025-04-28 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-28 | Janssen Research & Development, LLC | $310 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-25 | Janssen Research & Development, LLC | $5,873 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody Antibody, i | 2025 | |
| 2025-04-24 | ABBVIE INC. | $256 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2025 |
| 2025-04-24 | Janssen Research & Development, LLC | $201 | Research payment | Cash or cash equivalent | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasi | 2025 | |
| 2025-04-24 | ABBVIE INC. | $179 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2025 |
| 2025-04-16 | Janssen Research & Development, LLC | $1,287 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-16 | Janssen Research & Development, LLC | $695 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | 2025 |
| 2025-04-11 | Janssen Research & Development, LLC | $17,828 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2025 | |
| 2025-04-04 | Janssen Research & Development, LLC | $2,500 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2025 |
| 2025-04-03 | Janssen Research & Development, LLC | $11,440 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2025 | |
| 2025-04-03 | Janssen Research & Development, LLC | $8,331 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2025 |
| 2025-04-01 | Janssen Research & Development, LLC | $23,126 | Research payment | Cash or cash equivalent | Levine Alliance Partnership | 2025 | |
| 2025-03-31 | Janssen Research & Development, LLC | $17,943 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2025 |
| 2025-03-31 | Janssen Research & Development, LLC | $442 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2025 |
| 2025-03-28 | Janssen Research & Development, LLC | $2,601 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2025 | |
| 2025-03-28 | Barco, Inc. | $296 | Food and Beverage (2 payments) | In-kind items and services | 2025 |
The latest 200 records of 243.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Monroe, NC, county Union County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Monroe, NC | County Union County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 36,759 | 250,958 | 10,730,404 |
| Population, 2020 census P1 | 34,562 | 238,267 | 10,439,388 |
| Median age B01002 | 35.5 | 39.2 | 39.1 |
| Under 18 B01001 | 24.5% | 25.6% | 21.8% |
| 65 and over B01001 | 14.9% | 13.5% | 17.2% |
| Households B11001 | 12,620 | 84,237 | 4,282,345 |
| Foreign born B05002 | 17.8% | 12.2% | 9.1% |
| Median household income B19013 | $72,540 | $102,900 | $72,388 |
| Median family income B19113 | $80,817 | $118,218 | $90,290 |
| Per capita income B19301 | $31,089 | $46,949 | $41,385 |
| Poverty rate B17001 | 13.3% | 7.7% | 13.0% |
| Unemployment rate B23025 | 4.6% | 4.2% | 4.7% |
| Civilian labor force B23025 | 18,613 | 132,592 | 5,336,863 |
| Mean commute (minutes) B08013 | 30.1 | 29.8 | 25.1 |
| Bachelor's degree or higher B15003 | 24.1% | 40.5% | 35.7% |
| Housing units B25001 | 13,469 | 88,851 | 4,895,668 |
| Owner-occupied B25003 | 61.6% | 81.6% | 66.6% |
| Renters B25003 | 38.4% | 18.4% | 33.4% |
| Median home value B25077 | $309,100 | $417,300 | $288,900 |
| Median gross rent B25064 | $1,246 | $1,496 | $1,228 |
| White, not Hispanic B03002 | 43.7% | 66.8% | 60.0% |
| Black B03002 | 19.7% | 10.9% | 20.0% |
| Hispanic or Latino B03002 | 30.9% | 13.4% | 11.3% |
| Asian B03002 | 1.0% | 4.5% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Monroe, NC.
Comments